Brainphonics

Brainphonics operates at the intersection of audiology, medical devices, neuroscience, and pediatric diagnostics. Its differentiation is the use of brain-response measurements to assess how patients process speech and everyday sound, rather than relying exclusively on behavioral responses or conventional audiometry. That approach is particularly relevant for children and other patients who may have difficulty reporting hearing challenges, and CORGEE is positioned for use by hearing-care professionals. The company describes CORGEE as CE-certified and clinically validated in 100 children with hearing aids and/or cochlear implants, providing a stronger evidence base than an early concept-stage diagnostic product. However, public information is limited regarding revenue, installed clinical sites, reimbursement, regulatory expansion, and direct competitors. Brainphonics therefore appears to occupy a specialized, research-led niche rather than a broadly established hearing-device category. Its market progress will likely depend on clinical adoption, practitioner training, integration with existing audiology workflows, and the ability to demonstrate economic value alongside diagnostic accuracy.

Brainphonics was founded in 2024 and is developing from a university-linked auditory-neuroscience project into a commercial medical-device company. The main inflection point is the transition from research capability to a defined product: CORGEE measures brain responses to natural speech and everyday sound and is described as a CE-certified system for hearing assessment. Clinical validation in 100 children using hearing aids and/or cochlear implants provides an important foundation for pediatric use cases, where conventional behavioral testing can be difficult. On Oct 1, 2026, Brainphonics won the HWL Visitors’ Choice Award 2026 at Healthcare Week Luxembourg, giving the company external recognition for its pediatric technology. Its current employee base is categorized at fewer than 10 people, and the company is hiring a Business Developer to grow software sales, signaling an early commercial-expansion phase. The near-term trajectory therefore appears centered on converting clinical evidence and regulatory readiness into customer deployments, while building sales capacity and practitioner adoption.